Drug intelligence / Profile preview

treosulfan + total marrow irradiation

Development stage: Unknown
Lead developer: medac
Modality: Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Intravenous, External Beam Radiation

Overview

Treosulfan-TMI is a conditioning regimen that combines treosulfan (an alkylating agent) with Total Marrow Irradiation (TMI) for use prior to allogeneic hematopoietic stem cell transplantation. This combination has been investigated particularly in patients with multiple myeloma (MM), including those with advanced and heavily pretreated disease. The regimen has demonstrated promising efficacy outcomes with acceptable transplant-related mortality, suggesting it may be beneficial in the context of MM treatment.

Other names: Treosulfan-TMITreosulfan/TMI

Targets

DNA

Beyond the preview

Go deeper on treosulfan + total marrow irradiation.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on treosulfan + total marrow irradiation.

Explore the full profile